|10th July 2020||David P Hochman||14,600||Grant/award etc.||$0.00|
|17th March 2020||Barbara White||15,606||Open or private purchase||$3.63||$56,649.78|
|17th March 2020||Robert Paul Discordia||2,840||Open or private purchase||$3.54||$10,053.60|
|17th March 2020||Yuval Cohen||4,300||Open or private purchase||$3.49||$15,007.00|
|17th March 2020||Craig Stuart Millian||2,000||Open or private purchase||$4.25||$8,500.00|
|6th February 2020||David P Hochman||20,000||Grant/award etc.||$0.00|
|12th November 2019||Yuval Cohen||1,430||Open or private purchase||$4.26||$6,091.80|
|12th November 2019||Barbara White||3,424||Open or private purchase||$4.38||$14,991.64|
|11th November 2019||Robert Paul Discordia||2,500||Open or private purchase||$4.62||$11,558.50|
|11th November 2019||Craig Stuart Millian||1,000||Open or private purchase||$4.38||$4,380.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. The company was founded on December 18, 2013.